Prescriber Criteria Form

Bosulif 2025 PA Fax 806-A v2 010125.docx Bosulif (bosutinib) Coverage Determination

This fax machine is located in a secure location as required by HIPAA regulations.

Complete/review information, sign and date. Fax signed forms to CVS Caremark at **<Plan Fax Number>**. Please contact CVS Caremark at **1-866-785-5714** with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Bosulif (bosutinib).

Drug Name:				
Bosulif (bosutinib)				
Patient Name:				
Patient ID:				
Patient DOB:	Patient Phone:	Patient Phone:		
Prescriber Name:				
Prescriber Address:				
City:	State:	Zip:		
Prescriber Phone:	Prescriber Fax:	Prescriber Fax:		
Diagnosis:	ICD Code(s):			

Please circle the appropriate answer for each question.				
1	Does the patient have a diagnosis of chronic myeloid leukemia (CML), including patients newly diagnosed with CML and patients who have received a hematopoietic stem cell transplant? [If no, then skip to question 3.]	Yes	No	
2	Has the patient experienced resistance or intolerance to at least ONE of the following: a) imatinib, b) dasatinib, c) nilotinib? [If yes, skip to question 4.] [If no, then no further questions.]	Yes	No	
3	Does the patient have a diagnosis of B-cell acute lymphoblastic leukemia (B-ALL), including patients who have received a hematopoietic stem cell transplant? [If no, then skip to question 7.]	Yes	No	
4	Was the diagnosis confirmed by detection of the Philadelphia chromosome or BCR-ABL gene? [If no, then no further questions.]	Yes	No	
5	Has the patient experienced resistance to an alternative tyrosine kinase inhibitor for the patient's diagnosis? [If no, then no further questions.]	Yes	No	

Prescr	iber (or Authorized) Signature: Date:		
, ,	ning this form, I attest that the information provided is accurate and true as of this date and the entation supporting this information is available for review if requested by the health plan.	hat the	
Comm			
8	Is the disease in the chronic phase or blast phase?	Yes	No
	eosinophilia and ABL1 rearrangement? [If no, then no further questions.]		
7	Does the patient have a diagnosis of myeloid and/or lymphoid neoplasms with	Yes	No
	[No further questions.]		
6	Is the patient negative for all of the following mutations: T315I, G250E, V299L, and F317L?	Yes	No